In this episode of MedInsights Unleashed, John Collins speaks with Professor Gregory Randolph MD, FACS, FACE, Bertucci Chair in Thyroid Surgical Oncology at Harvard Medical School, about the evolving role of neoadjuvant therapy in advanced thyroid cancer.

The discussion explores the challenges of locally invasive thyroid cancer and how neoadjuvant lenvatinib prior to surgery may help improve surgical outcomes, reduce morbidity, and preserve critical structures such as the recurrent laryngeal nerve.

The conversation also highlights findings from a multicenter Phase 2 clinical trial, including promising results related to nerve preservation, vocal cord recovery, and the future of multidisciplinary thyroid cancer care.